Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Return on Sales (2021 - 2025)

Historic Return on Sales for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to 0.02%.

  • Verrica Pharmaceuticals' Return on Sales rose 128100.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79%, marking a year-over-year increase of 58700.0%. This contributed to the annual value of 9.77% for FY2024, which is 33000.0% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Return on Sales stood at 0.02%, which was up 128100.0% from 0.03% recorded in Q2 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' Return on Sales peaked at 0.18% during Q3 2022, and registered a low of 178.08% during Q1 2023.
  • Its 5-year average for Return on Sales is 28.25%, with a median of 8.49% in 2023.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Return on Sales plummeted by -1584300bps in 2023, and later skyrocketed by 1727700bps in 2024.
  • Verrica Pharmaceuticals' Return on Sales (Quarter) stood at 2.92% in 2021, then plummeted by -2881bps to 87.13% in 2022, then surged by 86bps to 12.4% in 2023, then plummeted by -218bps to 39.4% in 2024, then skyrocketed by 100bps to 0.02% in 2025.
  • Its last three reported values are 0.02% in Q3 2025, 0.03% for Q2 2025, and 2.91% during Q1 2025.